Application of autoantibodies in management of dermatomyositis patients

doi:10.3877/cma.j.issn.1674-0785.2022.08.017

Abstract

Abstract:

Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM). DM patients are usually accompanied by extramuscular manifestations such as arthritis, cardiomyopathy, interstitial lung disease (ILD), and malignant tumors. ILD and associated malignant tumors are the main causes of death in DM patients. Because the clinical characteristics, treatment response, and prognosis of DM patients are very different, it is very important to predict the prognosis of DM patients before treatment. Myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) can not only be used for diagnosis, but they are also useful for predicting the clinical characteristics, response to treatment, and prognosis of DM patients, which is helpful to better manage DM patients in routine clinical practice. This review describes how to incorporate autoantibody results into clinical practice in patients with DM, mainly adult patients.

Key words: Autoantibodies, Biomarkers, Dermatomyositis, Interstitial lung disease, Malignant tumors

Yafei Wang, Zhenbiao Wu. Application of autoantibodies in management of dermatomyositis patients[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 796-800.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.08.017

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I08/796

References 57

1	Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies [J].Lancet Neurol, 2018, 17(9): 816-828.
2	Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer [J]. Front Immunol, 2017, 8: 992.
3	Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link [J]. Autoimmun Rev, 2010,9(6):449-453.
4	Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis [J]. Curr Rheumatol Rep, 2012, 14(3): 275-285.
5	Gono T, Kuwana M. Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis [J]. Nat Rev Rheumatol, 2016, 12(9): 504-506.
6	Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by monoand multispecific immunoassays [J]. Autoimmun Rev, 2019, 18(3): 293-305.
7	Kuwana M. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting [J]. J Nippon Med Sch, 2017, 84(2): 56-63.
8	Ohtsuka T. The relation between nailfold bleeding and capillary microscopic abnormality in patients with connective tissue diseases [J]. Int J Dermatol, 1998, 37(1): 23-26.
9	Narang NS, Casciola-Rosen L, Li S, et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease [J]. Arthritis Care Res (Hoboken), 2015, 67(5): 667-672.
10	Didona D, Juratli HA, Scarsella L. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria [J]. Eur J Dermatol, 2020, 30(3): 279-288.
11	Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease [J]. Lupus, 2016, 25(8): 925-933.
12	Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome [J]. PLoS One, 2013, 8(4): e60442.
13	Hozumi H, Enomoto N, Kono M, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study [J]. PLoS One, 2015, 10(3): e0120313.
14	Nishio M, Endo Y, Kosaka K. Anti-aminoacyl-tRNA synthetases antibody positive overlap syndrome of systemic sclerosis and dermatomyositis associated with rapidly progressive interstitial lung disease [J]. J Dermatol, 2021, 48(2): e110-e111.
15	Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes [J]. J Intern Med, 2016, 280(1): 24-38.
16	Iwata N, Nakaseko H, Kohagura T, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan [J]. Mod Rheumatol, 2019, 29(5): 802-807.
17	Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis [J]. Clin Rheumatol, 2015, 34(9): 1627-1631.
18	Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies [J]. Curr Opin Neurol, 2016, 29(5): 662-673.
19	González-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review [J]. Rheumatol Int, 2018, 38(7): 1293-1296.
20	Aoyama J, Hayashi H, Yajima C, et al. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations [J]. Respir Med Case Rep, 2019, 26: 193-196.
21	Sakamoto N, Ishimoto H, Nakashima S, et al. Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis [J]. Intern Med, 2019, 58(6): 837-841.
22	Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease [J]. Respir Med, 2016, 121: 91-99.
23	Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies [J]. PLoS One, 2016, 11(4): e0154285.
24	Luo L, Huang WH, Ren FF. Pharyngeal ulceration and perforation: a rare manifestation in anti-MDA5 dermatomyositis [J]. Rheumatology (Oxford), 2021, 60(4): e132-e133.
25	Kanaoka M, Yamaguchi K, Watanabe T. Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1-γ autoantibody positivity [J]. Rheumatology (Oxford), 2020, 59(10): e68-e69.
26	Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis [J]. J Am Acad Dermatol, 2015, 72(3): 449-455.
27	DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis [J]. J Am Acad Dermatol, 2020, 82(2): 267-281.
28	Chung MP, Richardson C, Kirakossian D. Calcinosis biomarkers in adult and juvenile dermatomyositis [J]. Autoimmun Rev, 2020, 19(6): 102533.
29	Vooght JD, Vulsteke JB, Haes PD. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen [J]. Rheumatology(Oxford), 2020, 59(3): 469-477.
30	Ikeda N, Yamaguchi Y, Kanaoka M. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis [J]. J Dermatol, 2020, 47(5): 490-496.
31	Sung Y, Jung S, Kim H, et al. Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study [J]. Clin Rheumatol, 2020, 39(11): 3409-3416.
32	Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins [J]. Arthritis Rheum, 2012, 64(2): 513-522.
33	Shimizu K, Kobayashi T, Kano M. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis [J]. J Dermatol, 2020, 47(1): 64-68.
34	Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study [J]. Arthritis Res Ther, 2017, 19(1): 259.
35	Okiyama N, Yamaguchi Y, Kodera M. et al. Distinct histopathologic patterns of finger eruptions in dermatomyositis based on myositis-specific autoantibody profiles [J]. JAMA Dermatol, 2019, 155(9): 1080-1082.
36	Ono N, Kai K, Maruyama A, et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients [J]. Rheumatology(Oxford), 2019, 58(5): 786-791.
37	DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis [J]. J Am Acad Dermatol, 2020, 82(2): 267-281.
38	Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies [J]. Curr Rheumatol Rep, 2018, 20(5): 28.
39	Monseau G, Landon-Cardinal O, Stenzel W. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy [J].J Am Acad Dermatol, 2020, 83(6): 1759-1763.
40	Albayda J, Pinal-Fernandez I, Huang W, et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk [J]. Arthritis Care Res (Hoboken), 2017, 69(11): 1771-1776.
41	Rogers A, Chung L, Li S, et al. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients [J]. Arthritis Care Res (Hoboken), 2017, 69(12): 1909-1914.
42	Liu Y, Zheng Y, Gang Q. Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies [J]. Eur J Neurol, 2020, 27(3): 514-521.
43	Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity [J]. J Pediatr, 2018, 195: 16-27.
44	Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts [J]. Sci Rep, 2017, 7(1): 188.
45	Gono T, Tanino Y, Nishikawa A, et al. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: a potential unique subset of dermatomyositis-associated interstitial lung disease [J]. Int J Rheum Dis, 2019, 22(8): 1582-1586.
46	Kishi T, Rider LG, Pak K, et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients [J]. Arthritis Care Res (Hoboken), 2017, 69(7): 1088-1094.
47	Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy [J]. J Neurol Neurosurg Psychiatry, 2016, 87(10): 1038-1044.
48	Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody [J]. Brain, 2016, 139(Pt 8): 2131-2135.
49	De Lorenzo R, Pinal-Fernandez I, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies [J]. Neurology, 2018, 90(23): e2068-e2076.
50	Spielmann L, Nespola B, Séverac F, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes [J]. Ann Rheum Dis, 2019, 78(8): 1101-1106.
51	Kaji K, Fertig N, Medsger TA, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement [J]. Arthritis Care Res (Hoboken), 2014, 66(4): 575-584.
52	Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer [J]. Br J Dermatol, 2013, 169(4): 838-847.
53	Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients [J]. Rheumatology (Oxford), 2018, 57(7): 1212-1221.
54	Tsuji H, Nakashima R, Hosono Y, et al. A multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis [J]. Arthritis Rheumatol, 2020, 72(3): 488-498.
55	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease [J].N Engl J Med, 2019, 381(3): 291-293.
56	Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease [J]. Rheumatology (Oxford), 2015, 54(8): 1420-1428.
57	Kawasumi H, Gono T, Kawaguchi Y, et al. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies [J]. Clin Med Insights Circ Respir Pulm Med, 2015, 9(Suppl 1): 9-17.

[1]	Lu Wang, Yang Fan. Advances in endometrial cancer-related biomarker research [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 511-516.
[2]	Xu Wei, Ge Zhang, Jinlin Wu. Monitoring and treatment of neonatal sepsis-induced coagulopathy [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 379-386.
[3]	Zeqian Li, Shaolong Hao, Bo Zhang, Kailun Ji, Wei Han. Research progress of peripheral blood non-coding RNA in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 217-220.
[4]	Xinyu Shi, Jinbing Sun, Songbing He. Progress of blood biomarkers in neoadjuvant chemoradiotherapy of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 228-233.
[5]	Chengren Zhang, Yaochun Lv, Xiongfei Yang, Binbin Du. Research progress on influencing factors and diagnostic biomarkers of anastomotic leakage in postoperative rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 152-157.
[6]	Shan Wang, Qing Ma, Lan Yao, Huayu Yang. Correlation between folic acid therapy and serum level of miR-150-5p in elderly patients undergoing maintenance hemodialysis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(03): 139-144.
[7]	Taotao Ren, Xi Qiao. Progress of research on early biomarkers of acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(01): 32-38.
[8]	Xing Cai, Wenjuan Zhang, Jiangquan Yu, Ruiqiang Zheng. Study on the prognostic value of plasma heparin-binding protein in the early diagnosis and prognosis of sepsis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(02): 168-177.
[9]	Huifeng Zhang, Peng Zhang, Xiaowei Zhu, Hong Yu. Research progress on exosomal long non-coding RNAs in gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(01): 46-49.
[10]	Rongju Wu, Pingchao Xiang. Correlation between frequent exacerbation phenotype of chronic obstructive pulmonary disease and inflammatory markers [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 939-947.
[11]	Yingjie Xu, Jia Zhu, Min Kang, Jun Hou, Gaixiu Su, Shengnan Li, Dan Zhang, Jianming Lai. Clinical characteristics of ten children with rheumatic diseases complicated with digestive tract perforation [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 648-654.
[12]	Yihan Wu, Zhang Lei, Hongda Lu. Progress in understanding of role of MUC16/CA125 in diagnosis and treatment of benign and malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 591-595.
[13]	Zejun Yang, Yin Zhao. Detection of autoantibodies in thrombophilia of pregnancy [J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2023, 12(02): 76-80.
[14]	Min Wang, Yan Zhang, Yingxi Wang, Long Zhao, Shuyue Xia. The roles of exosomes in chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 45-51.
[15]	Fangfang Guo, Minmin Li. Research progress on non-invasive biomarkers of lupus nephritis [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 271-275.

Please choose a citation manager

Content to export